Survival Rate
Zanidatamab Demonstrates Promising 30-Month Survival Rate in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
Zanidatamab, HER2-positive, metastatic gastroesophageal adenocarcinoma, bispecific antibody, survival rate, gastric cancer, oncology.
RYBREVANT: A Breakthrough in Lung Cancer Treatment
RYBREVANT, lung cancer, EGFR mutations, subcutaneous administration, intravenous administration, infusion-related reactions, survival rate, non-small cell lung cancer (NSCLC)